A Phase II Evaluation Of CT-2103 [paclitaxel poliglumex] (IND 61013) In The Third-Line Treatment Of Recurrent Or Persistent Epithelial Ovarian or Primary Peritoneal Cancer.
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Paclitaxel poliglumex (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Feb 2008 Status changed from in progress to completed.
- 24 Sep 2005 New trial record.